Abstract
Recently, a mechanism of negative regulation of immune responses by a specialized population of so-called regulatory T cells (Tregs) has become a focus of intense investigation. Through the discovery of transcription factor Foxp3 as a central molecular determinant of Tregs differentiation and function, the complex biology of these cells, including maintenance of immunological tolerance to “self” and regulation of immune responses to pathogens, commensals, and tumors, has become the focus of intense investigation. The ability to control the infection and to delay the progression of the infection to AIDS and/or death is probably regulated by a balance between host factors, such as immunologic response and viral factors. Different rates of disease progression among HIV-1 infected individuals have been observed. In this context, Tregs may play an important role in the immunopathology of HIV-1 infection due to their potent suppressive activity of both T cell activation and effector function. In this review, we present the molecular and immunological aspects of Tregs in the HIV system and the association between Tregs and highly active antiretroviral therapy (HAART).
Keywords: Regulatory T cells, HIV, Foxp3, highly active antiretroviral therapy
Current HIV Research
Title: Involvement of Regulatory T Cells in HIV Immunopathogenesis
Volume: 8 Issue: 4
Author(s): Sara S. Bernardes, Isabele K. Borges, Juliana E. Lima, Paula de Azevedo O. Milanez, Ivete Conchon-Costa, Ionice Felipe, Halha O. Saridakis and Maria A.E. Watanabe
Affiliation:
Keywords: Regulatory T cells, HIV, Foxp3, highly active antiretroviral therapy
Abstract: Recently, a mechanism of negative regulation of immune responses by a specialized population of so-called regulatory T cells (Tregs) has become a focus of intense investigation. Through the discovery of transcription factor Foxp3 as a central molecular determinant of Tregs differentiation and function, the complex biology of these cells, including maintenance of immunological tolerance to “self” and regulation of immune responses to pathogens, commensals, and tumors, has become the focus of intense investigation. The ability to control the infection and to delay the progression of the infection to AIDS and/or death is probably regulated by a balance between host factors, such as immunologic response and viral factors. Different rates of disease progression among HIV-1 infected individuals have been observed. In this context, Tregs may play an important role in the immunopathology of HIV-1 infection due to their potent suppressive activity of both T cell activation and effector function. In this review, we present the molecular and immunological aspects of Tregs in the HIV system and the association between Tregs and highly active antiretroviral therapy (HAART).
Export Options
About this article
Cite this article as:
S. Bernardes Sara, K. Borges Isabele, E. Lima Juliana, de Azevedo O. Milanez Paula, Conchon-Costa Ivete, Felipe Ionice, O. Saridakis Halha and A.E. Watanabe Maria, Involvement of Regulatory T Cells in HIV Immunopathogenesis, Current HIV Research 2010; 8 (4) . https://dx.doi.org/10.2174/157016210791208613
DOI https://dx.doi.org/10.2174/157016210791208613 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Sugar-Base Anhydro Bridge for Modification of Nucleosides in the 2’- and/or 3’-Positions - Revisited
Current Organic Chemistry Nucleosides with Modified Sugar Ring: Synthesis and Biological Activities
Current Organic Chemistry Targeting Phosphatidylserine in Anti-Cancer Therapy
Current Pharmaceutical Design Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1
Current Topics in Medicinal Chemistry Recent Approaches to Improve the Antitumor Efficacy of Temozolomide
Current Medicinal Chemistry Tumour Gene Therapy Monitoring Using Magnetic Resonance Imaging and Spectroscopy
Current Gene Therapy Inhibition of HIV-1 Replication by RNA-Based Strategies
Current HIV Research Molecular Recognition Mechanisms for Detecting Cell Death In Vivo
Current Pharmaceutical Biotechnology The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer
Clinical Cancer Drugs Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Infrequent Infections in COPD
Current Respiratory Medicine Reviews Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Ribonucleotide Reductase: A Mechanistic Portrait of Substrate Analogues Inhibitors
Current Medicinal Chemistry Development of Heparanase Inhibitors for Anti-Cancer Therapy
Current Medicinal Chemistry Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews Precision Tumor Medicine and Drug Targets
Current Topics in Medicinal Chemistry Cycloxygenase-2 (COX-2) - A Potential Target for Screening of Small Molecules as Radiation Countermeasure Agents: An In Silico Study
Current Computer-Aided Drug Design Genomics and Pharmacogenomics of Brain Disorders
Current Pharmaceutical Biotechnology Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets